USPTO serial 88173138
SECOND BRAIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DUBRAY, KATHERINE M
- Law office
- TTAB
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with SECOND BRAIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian E. Turung
BRIAN E TURUNG FAY SHARPE LLP1228 EUCLID AVENUECLEVELAND, OH 44115UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and/or minerals and/or essential fatty acids and/or probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; preparations in the nature of a vaginal probiotic for the treatment and/or prevention of bacterial or fungal vaginal infection; nutraceuticals for the treatment and/or prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, including, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for improving the physical well-being of humans, namely, reducing inflammation and pain; supplements, namely, dietary supplements, for medical use and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and/or nutritional and dietary supplements vaginal antifungal preparations; fungal and/or bacterial probiotics, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; nutritional supplements, namely, probiotic compositions; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; diagnostic test kit comprised of medical diagnostic reagents and assays for the detection of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; diagnostic colon test kit comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, Crohn's disease, ulcerative colitis, and irritable bowel syndrome; diagnostic colon cancer test kit comprised of medical diagnostic reagents and assays; diagnostic colorectal cancer screening test kit comprised of medical diagnostic reagents and assays; all of the aforementioned supplements and pharmaceutical products for human consumption containing probiotics; all of the aforementioned diagnostic kits testing levels of probiotics | ABANDONED | — |
| 044 | Medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the gastrointestinal tract; Medical diagnostic testing services to detect bacteria, fungus, microorganisms, probiotics, cancer and/or pathogens in the large intestine; Medical diagnostic testing services to apprise individuals and/or animals of the status of the gastrointestinal tract; Medical diagnostic testing services to apprise individuals and/or animals of the status of the large intestine; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the gastrointestinal tract; providing medical information comprised of a personalized report comparing detected levels of bacteria, fungus, microorganisms, probiotics, cancer and/or pathogen in the large intestine; providing educational information in the field of the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganism, probiotics, cancer and/or pathogens in the gastrointestinal tract; providing educational information in the field of the gastrointestinal tract and the existence and reason for bacteria, fungus, microorganism, probiotics, cancer and/or pathogens in the large intestine; providing educational information in the field of the gastrointestinal tract and how to have and maintain and/or monitor a healthy gastrointestinal tract; providing educational information in the field of the gastrointestinal tract and how to have and maintain and/or monitor a healthy large intestine | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BIOHM HEALTH LLC
- Other trademarks owned by BIOHM HEALTH LLC
- Other trademarks owned by PathoBiome LLC
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named SECOND BRAIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 9, 2020 | MAB4 | ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION | — |
| Mar 9, 2020 | ABN4 | ABANDONMENT - AFTER INTER PARTES DECISION | — |
| Mar 9, 2020 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Mar 9, 2020 | OP.S | OPPOSITION SUSTAINED NO. 999999 | — |
| Dec 6, 2019 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Nov 5, 2019 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Oct 8, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 8, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 18, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 5, 2019 | ALIE | ASSIGNED TO LIE | — |
| Aug 30, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 13, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 28, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 30, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 13, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |